Childress Capital Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Childress Capital Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,951 shares of the biopharmaceutical company’s stock after selling 982 shares during the period. Childress Capital Advisors LLC’s holdings in Pfizer were worth $1,301,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Nicholas Hoffman & Company LLC. raised its holdings in shares of Pfizer by 1.2% in the 3rd quarter. Nicholas Hoffman & Company LLC. now owns 44,763 shares of the biopharmaceutical company’s stock worth $1,295,000 after purchasing an additional 533 shares during the period. Fidelis Capital Partners LLC raised its holdings in Pfizer by 5.2% in the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 1,267 shares during the period. GW Henssler & Associates Ltd. purchased a new stake in Pfizer during the third quarter worth approximately $289,000. Diversify Advisory Services LLC increased its position in shares of Pfizer by 3.7% in the third quarter. Diversify Advisory Services LLC now owns 406,186 shares of the biopharmaceutical company’s stock worth $11,714,000 after acquiring an additional 14,457 shares in the last quarter. Finally, Integrated Advisors Network LLC raised its stake in shares of Pfizer by 18.3% in the 3rd quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 9,925 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Price Performance

PFE opened at $28.47 on Wednesday. The company has a market capitalization of $161.33 billion, a P/E ratio of -61.89, a PEG ratio of 0.99 and a beta of 0.67. The company has a 50-day moving average of $29.07 and a 200-day moving average of $28.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the company earned $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.90%. Pfizer’s dividend payout ratio (DPR) is -365.21%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.